{
    "organizations": [],
    "uuid": "e8706a9269a527dd75c11f025f5eea335e7fa2b2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-halozyme-reports-q1-loss-per-share/brief-halozyme-reports-q1-loss-per-share-0-19-idUSASC0A1KI",
    "ord_in_thread": 0,
    "title": "BRIEF-Halozyme Reports Q1 Loss Per Share $0.19",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Halozyme Therapeutics Inc:\n* Q1 LOSS PER SHARE $0.19 * Q1 REVENUE $30.9 MILLION VERSUS I/B/E/S VIEW $31.8 MILLION\n* Q1 EARNINGS PER SHARE VIEW $-0.22 â€” THOMSON REUTERS I/B/E/S\n* SEES FY 2018 NET REVENUE OF $115 MILLION TO $125 MILLION, INCLUDING 25 TO 30 PERCENT ROYALTY GROWTH Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T04:39:00.000+03:00",
    "crawled": "2018-05-11T12:46:43.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "halozyme",
        "therapeutic",
        "inc",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "see",
        "fy",
        "net",
        "revenue",
        "million",
        "million",
        "including",
        "percent",
        "royalty",
        "growth",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}